ResearcherUniversity of TsukubaNo recent work listed
Nobuhiro Ohkohchi
Matched on ORCID iD 0000-0003-2779-1247; OpenAlex author ID A5060223389. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 7)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers
Papers 7
- Remnant pancreatic volume as an indicator of poor prognosis in pancreatic cancer patients after resection. Last author DOI 10.1016/j.pan.2019.05.464↗
- Three-Dimensional Remnant Pancreatic Volumetry Predicts Postoperative Pancreatic Fistula in Pancreatic Cancer Patients after Pancreaticoduodenectomy. Last author DOI 10.1159/000495406↗
- A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin-Drug Conjugate (LDC). Last author DOI 10.1158/1535-7163.mct-17-0232↗
- Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000697↗
- Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic cancer. Last author DOI 10.1111/cas.12888↗
- Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. Last author DOI 10.1038/bjc.2014.49↗
- Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer. Last author DOI 10.1111/cas.12198↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ryoichi Miyamoto · 6 shared papers, 2013–2019 · strength 0.44
- Paper Remnant pancreatic volume as an indicator of poor prognosis in pancreatic cancer patients after resection. DOI 10.1016/j.pan.2019.05.464↗
- Paper Three-Dimensional Remnant Pancreatic Volumetry Predicts Postoperative Pancreatic Fistula in Pancreatic Cancer Patients … DOI 10.1159/000495406↗
- Paper Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. DOI 10.1097/mpa.0000000000000697↗
- Tatsuya Oda · 5 shared papers, 2013–2018 · strength 0.27
- Paper A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin-Drug Conjugate … DOI 10.1158/1535-7163.mct-17-0232↗
- Paper Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. DOI 10.1097/mpa.0000000000000697↗
- Paper Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic can… DOI 10.1111/cas.12888↗
- Yusuke Ohara · 4 shared papers, 2013–2017 · strength 0.19
- Paper Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. DOI 10.1097/mpa.0000000000000697↗
- Paper Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic can… DOI 10.1111/cas.12888↗
- Paper Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that … DOI 10.1038/bjc.2014.49↗
- Tsuyoshi Enomoto · 4 shared papers, 2013–2017 · strength 0.19
- Paper Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. DOI 10.1097/mpa.0000000000000697↗
- Paper Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic can… DOI 10.1111/cas.12888↗
- Paper Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that … DOI 10.1038/bjc.2014.49↗
- Yoshimasa Akashi · 4 shared papers, 2013–2017 · strength 0.19
- Paper Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. DOI 10.1097/mpa.0000000000000697↗
- Paper Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic can… DOI 10.1111/cas.12888↗
- Paper Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that … DOI 10.1038/bjc.2014.49↗
- Tomohiro Kurokawa · 3 shared papers, 2014–2017 · strength 0.16
- Paper Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic Cancer. DOI 10.1097/mpa.0000000000000697↗
- Paper Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic can… DOI 10.1111/cas.12888↗
- Paper Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that … DOI 10.1038/bjc.2014.49↗
- Osamu Shimomura · 2 shared papers, 2016–2018 · strength 0.13
- Paper A Novel Therapeutic Strategy for Pancreatic Cancer: Targeting Cell Surface Glycan Using rBC2LC-N Lectin-Drug Conjugate … DOI 10.1158/1535-7163.mct-17-0232↗
- Paper Cetuximab delivery and antitumor effects are enhanced by mild hyperthermia in a xenograft mouse model of pancreatic can… DOI 10.1111/cas.12888↗
- Sota Kimura · 1 shared paper, 2018 · strength 0.08
- Hiroaki Tateno · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.